Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

P MUC1C ALLO1

Next Previous
Drug Profile

P MUC1C ALLO1

Alternative Names: P-MUC1C-101; P-MUC1C-ALLO1

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poseida Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 24 Apr 2025 Discontinued - Phase-I for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV) prior to April 2025 (Roche pipeline, April 2025) (Poseida Therapeutics pipeline, June 2025)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
  • 15 Nov 2024 Efficacy data from a phase I trial in Solid tumours released by Poseida Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top